MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1177/15209156251376654

Медицинская библиотека · Diabetes technology & therapeutics · 2025

Real-World Effectiveness of the MiniMed™ 780G Advanced Hybrid Closed-Loop System for People ≥65 Years with Type 1 or Type 2 Diabetes in the United States.

Chien Albert, Shin John J, Liu Margaret, Arrieta Arcelia, Cordero Toni L, Swensen Andrine R, Vigersky Robert A

СтатьяПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

Objective

Multiple daily injections therapy in older adults with diabetes can negatively impact glycemic control and comorbidities. This issue may be overcome with advanced diabetes technology that reduces hypoglycemia and hyperglycemia. The present study evaluated real-world glycemic outcomes of a United States (US) cohort ≥65 years using the MiniMed™ 780G (MM780G) advanced hybrid closed-loop system.

Methods

CareLink™ personal data as of December 18, 2024, for U.S. MM780G system users ≥65 years, were de-identified and analyzed. Metrics, including time in range (TIR 70-180 mg/dL), time in tight range (TITR 70-140 mg/dL), time below range 70 mg/dL (TBR70), and time above range 180 mg/dL and 250 mg/dL (TAR180 and TAR250, respectively), with and without recommended optimal settings (ROS, 100 mg/dL glucose target with 2 h active insulin time) were determined. Subanalyses based on age group (≥75 years) and type 1 diabetes (T1D) or type 2 diabetes (T2D) were, also, conducted.

Results

The overall cohort (n = 8542) had a mean TIR, TITR, TBR70, TAR180, and TAR250 of 78.4%, 51.4%, 0.9%, 20.7%, and 3.6%, respectively, with a 6.8% glucose management indicator. For ROS users (n = 2753), TIR and TITR were higher (81.9% and 55.9%, respectively, P < 0.001), and TAR180 and TAR250 were lower (17.2% and 2.5%, respectively, P < 0.001). Data trended similarly among the population aged ≥75 years, and no differences were observed between T1D and T2D.

Conclusions

In a real-world setting, a U.S. cohort aged ≥65 years using the MM780G system achieved consensus-recommended glycemic targets. Use of ROS enabled more users to achieve an even higher level of glycemic control.

Для цитирования: Chien Albert, Shin John J, Liu Margaret, Arrieta Arcelia, Cordero Toni L, Swensen Andrine R, Vigersky Robert A. Real-World Effectiveness of the MiniMed™ 780G Advanced Hybrid Closed-Loop System for People ≥65 Years with Type 1 or Type 2 Diabetes in the United States.. Diabetes technology & therapeutics. 2025. DOI: 10.1177/15209156251376654.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.